2024 ASCO® Annual Meeting Insights Hub

Meeting coverage & Vumedi’s exclusive highlights, all in one place.

 

ASCO® 2024 Insights: "NEO-TIM Trial - Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-Risk Resectable Melanoma"

33 views
June 12, 2024
0 Comments
Login to view comments. Click here to Login
Skin